Insights to Impact :
A Selection of Out Recent Work

A group asked DeciBio to identify and evaluate clinical genetic testing labs for potential acquisition

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

A real-world data (RWD) provider wanted to identify key use cases, unmet needs, and future opportunities in the RWD market, with a particular focus on clinical, genomic, and pathology RWD and biopharma users.

A large life science tools provider was interested in characterizing the genome engineering and engineered cell line market to identify potential opportunities to participate in the space

A diagnostics company requested DeciBio to help an advisory board (ad board) to understand how to position its relatively new somatic oncology genomics profiling product in an already competitive market

DeciBio conducted financial projections, valuation, and assisted with messaging to aid client's public listing to NASDAQ